FAQ on Clene's Participation in the Canaccord Genuity 44th Annual Growth Conference
Summary
What is Clene Inc. known for?
Clene Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases such as ALS, Parkinson’s disease, and multiple sclerosis.
Why is Clene’s participation in the Canaccord Genuity 44th Annual Growth Conference significant?
This participation provides Clene with a platform to present its research and developments in treating neurodegenerative diseases, potentially attracting investor interest and partnerships.
How can I view Clene’s presentation at the conference?
The live webcast of Clene’s presentation can be viewed at https://ibn.fm/uGo0W.
When is Clene’s presentation scheduled?
Clene’s presentation is scheduled for August 13, 2024, at 11:30 a.m. EST.
What is CNM-Au8(R)?
CNM-Au8(R) is an investigational first-in-class therapy by Clene that aims to improve central nervous system cells’ survival and function by targeting mitochondrial function and the NAD pathway while reducing oxidative stress.
Where is Clene Inc. based?
Clene Inc. is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland.
Who can I contact for more information about Clene Inc.?
For more information, you can visit www.Clene.com or contact IBN (InvestorBrandNetwork) at Editor@InvestorBrandNetwork.com.
What are the implications of Clene’s research for neurodegenerative diseases?
Clene’s research could lead to innovative treatments that improve mitochondrial health and protect neuronal function, offering new hope for patients with neurodegenerative diseases like ALS, Parkinson’s, and MS.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 130247